Astrocyte Pharmaceuticals

Astrocyte Pharmaceuticals is a clinical-stage drug discovery and development company founded in 2014 that is dedicated to accelerating the recovery and well-being of brain injury patients. The company's slogan, "A Novel Approach to Neuroprotection," reflects its commitment to proving the neuro- and cerebroprotective benefits of enhanced mitochondrial energy production in astrocytes. Astrocyte is advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease. Most recently, Astrocyte Pharmaceuticals raised a total of $6.00M in its Series B investment at 18 August 2023. The funding round attracted investment from a diverse group of investors, including Boston Harbor Angels, Life Science Angels, NAVIS, Deepwork Capital, Mass Medical Angels, Mid-Atlantic Bio Angels, Sidecar Angels, Dreavent Capital, Alzheimer's Drug Discovery Foundation, and Trend Investment Group. Based in the United States, Astrocyte Pharmaceuticals operates within the biotechnology and pharmaceutical industries. Overall, Astrocyte Pharmaceuticals stands at the forefront of advancing novel therapies for brain injuries and neurodegenerative disorders, thus garnering significant support from a diverse group of investors, including prominent names in the life sciences and healthcare investment space.